{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:21:03Z","timestamp":1793985663047,"version":"4.8.0"},"reference-count":171,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Neutralizing antibodies (NAbs) have long been the principal correlate of antiviral protection. Evidence now indicates that antibody Fc-mediated effector functions play indispensable and context-dependent roles in antiviral immunity. Through interactions between the fragment crystallizable (Fc) domain and Fc receptors (FcRs) or complement components, antibodies mediate a broad spectrum of effector mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular and neutrophil phagocytosis (ADCP and ADNP), and complement activation, contributing to viral control beyond direct neutralization. In this review, we integrate recent evidence on Fc effector biology across major viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus, human immunodeficiency virus (HIV), Ebola virus (EBOV), and dengue virus (DENV). We discuss how Fc-FcR interactions shape antiviral immune outcomes, modulate vaccine efficacy, and influence the balance between protective immunity and immunopathology, including antibody-dependent enhancement (ADE). We focus on the experimental strategies used to assess Fc-mediated functions and on the inherent limitations of\n                    <jats:italic>in vitro<\/jats:italic>\n                    assays and animal models in defining their physiological relevance in humans. We explore how different vaccine platforms and immunization strategies shape Fc effector profiles, specifically through antibody subclass selection, Fc glycosylation patterns, and engagement with Fc\u03b3 receptors. We also summarize emerging approaches to Fc engineering and glycan modification that aim to enhance antibody efficacy while limiting adverse immune activation. This review summarizes current understanding of Fc effector functions in antiviral immunity and discusses their relevance for the design of next-generation vaccines and antibody-based therapies.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1772257","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:31:24Z","timestamp":1778477484000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Fc effector functions in RNA viral infections: mechanisms of antiviral immunity and implications for vaccine design"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiale","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Jiangsu University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Joint Institute of Nanjing Drum Tower Hospital for Life and Health, College of Life Science, Nanjing Normal University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research Center, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Jiangsu University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aofan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Jiangsu University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Joint Institute of Nanjing Drum Tower Hospital for Life and Health, College of Life Science, Nanjing Normal University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Jiangsu University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/v15010001","article-title":"A glimpse on the evolution of RNA viruses: Implications and lessons from SARS-CoV-2","volume":"15","author":"Simicic","year":"2022","journal-title":"Viruses"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00858-w","article-title":"Antiviral neutralizing antibodies: from in vitro to in vivo activity","volume":"23","author":"Burton","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.08.015","article-title":"Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy","volume":"54","author":"Ullah","year":"2021","journal-title":"Immunity"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168947","article-title":"The role of Fc receptors on the effectiveness of therapeutic monoclonal antibodies","volume":"22","author":"Gogesch","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2016.09.002","article-title":"Modulating antibody functionality in infectious disease and vaccination","volume":"22","author":"Gunn","year":"2016","journal-title":"Trends Mol Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010016","article-title":"Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials","volume":"17","author":"Fischinger","year":"2021","journal-title":"PloS Pathog"},{"key":"B8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/imr.12343","article-title":"Fcgamma receptor pathways during active and passive immunization","volume":"268","author":"Bournazos","year":"2015","journal-title":"Immunol Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110174","article-title":"Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques","volume":"27","author":"Tong","year":"2024","journal-title":"iScience"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2434567","article-title":"CoronaVac-induced antibodies that facilitate Fc-mediated neutrophil phagocytosis track with COVID-19 disease resolution","volume":"14","author":"Li","year":"2025","journal-title":"Emerg Microbes Infect"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100290","article-title":"Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset","volume":"2","author":"Anand","year":"2021","journal-title":"Cell Rep Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100420","article-title":"Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model","volume":"2","author":"Patel","year":"2021","journal-title":"Cell Rep Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abp9770","article-title":"Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity","volume":"8","author":"Lopez-Munoz","year":"2022","journal-title":"Sci Adv"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7358","DOI":"10.1038\/s41467-024-51427-1","article-title":"Antibody Fc receptor binding and T cell responses to homologous and heterologous immunization with inactivated or mRNA vaccines against SARS-CoV-2","volume":"15","author":"Cohen","year":"2024","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.838780","article-title":"SARS-coV-2 spike- and nucleoprotein-specific antibodies induced after vaccination or infection promote classical complement activation","volume":"13","author":"Lamerton","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiae017","article-title":"SARS-CoV-2 membrane protein-specific antibodies from critically ill SARS-CoV-2-infected individuals interact with Fc receptor-expressing cells but do not neutralize the virus","volume":"115","author":"Fernandez-Soto","year":"2024","journal-title":"J Leukoc Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj9534","article-title":"C1q enables influenza hemagglutinin stem binding antibodies to block viral attachment and broadens the antibody escape repertoire","volume":"9","author":"Kosik","year":"2024","journal-title":"Sci Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae241","article-title":"Hemagglutinin stalk-specific Fc-mediated functions are associated with protection against influenza illness after seasonal influenza vaccination","volume":"230","author":"Motsoeneng","year":"2024","journal-title":"J Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01463-17","article-title":"Influenza virus hemagglutinin stalk-specific antibodies in human serum are a surrogate marker for in vivo protection in a serum transfer mouse challenge model","volume":"8","author":"Jacobsen","year":"2017","journal-title":"mBio"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01624-16","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies induce potent phagocytosis of immune complexes by neutrophils in an Fc-dependent manner","volume":"7","author":"Mullarkey","year":"2016","journal-title":"mBio"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-017-0011-8","article-title":"Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes","volume":"2","author":"Wohlbold","year":"2017","journal-title":"Nat Microbiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/v15071540","article-title":"Fc-effector-independent in vivo activity of a potent influenza B neuraminidase broadly neutralizing antibody","volume":"15","author":"Khalil","year":"2023","journal-title":"Viruses"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002011","article-title":"Antibody-dependent cellular cytotoxicity in HIV infection","volume":"32","author":"Forthal","year":"2018","journal-title":"AIDS"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126391","article-title":"Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk","volume":"129","author":"Neidich","year":"2019","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030441","article-title":"Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection","volume":"3","author":"Huber","year":"2006","journal-title":"PloS Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001812","article-title":"Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity","volume":"32","author":"Chung","year":"2018","journal-title":"AIDS"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.682120","article-title":"Associations between antibody Fc-mediated effector functions and long-term sequelae in Ebola virus survivors","volume":"12","author":"Paquin-Proulx","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112402","article-title":"Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates","volume":"42","author":"Gunn","year":"2023","journal-title":"Cell Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm3151","article-title":"Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection","volume":"14","author":"Dias","year":"2022","journal-title":"Sci Transl Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"100057","DOI":"10.1074\/jbc.REV120.013168","article-title":"Fc gamma receptor compositional heterogeneity: Considerations for immunotherapy development","volume":"296","author":"Barb","year":"2021","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/82_2010_86","article-title":"FcgammaRs in health and disease","volume":"350","author":"Nimmerjahn","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13393","article-title":"Fc-FcgammaR interactions during infections: From neutralizing antibodies to antibody-dependent enhancement","volume":"328","author":"Edgar","year":"2024","journal-title":"Immunol Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12331","article-title":"The multiple facets of FcRn in immunity","volume":"268","author":"Stapleton","year":"2015","journal-title":"Immunol Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00945","article-title":"Functional roles of the IgM Fc receptor in the immune system","volume":"10","author":"Kubagawa","year":"2019","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S266242","article-title":"IgA and FcalphaRI: Versatile players in homeostasis, infection, and autoimmunity","volume":"9","author":"van Gool","year":"2020","journal-title":"Immunotargets Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"B978","DOI":"10.1016\/B978-0-12-801238-3.00119-7","article-title":"Fc receptors in immune responses","author":"Mancardi","year":"2014","journal-title":"Reference Module Biomed Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01958","article-title":"Expression, role, and regulation of neutrophil Fcgamma receptors","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0902454","article-title":"The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM- and ITAM-containing Fcgamma receptors FcgammaRIIB and FcgammaRIIA","volume":"73","author":"Huang","year":"2003","journal-title":"J Leukoc Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1134\/S0006297925602795","article-title":"Molecular mechanisms of antibody-dependent enhancement of viral infection","volume":"91","author":"Filatov","year":"2026","journal-title":"Biochem (Mosc)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00410-0","article-title":"The role of IgG Fc receptors in antibody-dependent enhancement","volume":"20","author":"Bournazos","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00332","article-title":"Antibody-dependent cellular phagocytosis in antiviral immune responses","volume":"10","author":"Tay","year":"2019","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00548","article-title":"Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease","volume":"10","author":"van Erp","year":"2019","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41598-022-27279-4","article-title":"Purified complement C3b triggers phagocytosis and activation of human neutrophils via complement receptor 1","volume":"13","author":"Boero","year":"2023","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.imlet.2021.06.006","article-title":"New aspects in the regulation of human B cell functions by complement receptors CR1, CR2, CR3 and CR4","volume":"237","author":"Erdei","year":"2021","journal-title":"Immunol Lett"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8378","article-title":"Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity","volume":"371","author":"Larsen","year":"2021","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s42003-024-06659-8","article-title":"Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing","volume":"7","author":"de Taeye","year":"2024","journal-title":"Commun Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108360108","article-title":"Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant","volume":"108","author":"Zeitlin","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1758338","article-title":"Immunoglobulin G N-glycosylation remodeling in viral infections: immunomodulatory roles and potential biomarker implications","volume":"17","author":"Yan","year":"2026","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108455108","article-title":"Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose","volume":"108","author":"Ferrara","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.96112","article-title":"Antibody-dependent enhancement of coronaviruses","volume":"21","author":"Tao","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B53","unstructured":"Coronavirus disease (COVID-19)\n          \n          2025"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1038\/s41467-025-59533-4","article-title":"SARS-CoV-2 virus lacking the envelope and membrane open-reading frames as a vaccine platform","volume":"16","author":"Kuroda","year":"2025","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01413-7","article-title":"Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals","volume":"27","author":"Kustin","year":"2021","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.07.020","article-title":"Distinct early serological signatures track with SARS-CoV-2 survival","volume":"53","author":"Atyeo","year":"2020","journal-title":"Immunity"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.052","article-title":"Compromised humoral functional evolution tracks with SARS-CoV-2 mortality","volume":"183","author":"Zohar","year":"2020","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1038\/s41467-023-40960-0","article-title":"SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations","volume":"14","author":"Hederman","year":"2023","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1038\/s41467-023-39189-8","article-title":"Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination","volume":"14","author":"Tong","year":"2023","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10060858","article-title":"Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-elicited IgG and neutralizing titers against SARS-CoV-2 and its variants","volume":"10","author":"Padhiar","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1382619","article-title":"Heterologous Ad26\/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities","volume":"15","author":"Klingler","year":"2024","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100405","article-title":"Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination","volume":"2","author":"Gorman","year":"2021","journal-title":"Cell Rep Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106473","article-title":"Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections","volume":"90","author":"Martin Perez","year":"2025","journal-title":"J Infect"},{"key":"B69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12979-024-00466-9","article-title":"Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults","volume":"21","author":"Gelderloos","year":"2024","journal-title":"Immun Ageing"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads1482","article-title":"Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant","volume":"11","author":"Aurelia","year":"2025","journal-title":"Sci Adv"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2023.0091","article-title":"Relationship between human FCgammaRIIA rs1801274 G allele and risk of death among different SARS-CoV-2 variants","volume":"36","author":"Moghaddam","year":"2023","journal-title":"Viral Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20011925","article-title":"Fc gamma receptors and cross-presentation in dendritic cells","volume":"195","author":"Amigorena","year":"2002","journal-title":"J Exp Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2838-z","article-title":"Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection","volume":"588","author":"Bournazos","year":"2020","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","volume":"184","author":"Winkler","year":"2021","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2314730121","article-title":"High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies","volume":"121","author":"Paciello","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41467-023-36761-0","article-title":"Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants","volume":"14","author":"Yu","year":"2023","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2021.03.009","article-title":"The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein","volume":"559","author":"Chen","year":"2021","journal-title":"Virology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.04.005","article-title":"High-affinity FcgammaRIIIa genetic variants and potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) responses contributing to severe COVID-19","volume":"24","author":"Vietzen","year":"2022","journal-title":"Genet Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41590-020-00828-7","article-title":"Proinflammatory IgG Fc structures in patients with severe COVID-19","volume":"22","author":"Chakraborty","year":"2021","journal-title":"Nat Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2101497118","article-title":"IgA potentiates NETosis in response to viral infection","volume":"118","author":"Stacey","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B81","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1038\/s41467-020-19568-1","article-title":"Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"B82","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s42003-022-03207-0","article-title":"Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires Fc\u03b3RIIB and virus-antibody complex with bivalent interaction","volume":"5","author":"Wang","year":"2022","journal-title":"Commun Biol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138999","article-title":"Neutrophil extracellular traps in COVID-19","volume":"5","author":"Zuo","year":"2020","journal-title":"JCI Insight"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.838011","article-title":"NETosis and neutrophil extracellular traps in COVID-19: Immunothrombosis and beyond","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01263-3","article-title":"Humoral signatures of protective and pathological SARS-CoV-2 infection in children","volume":"27","author":"Bartsch","year":"2021","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04017-w","article-title":"Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy","volume":"599","author":"Yamin","year":"2021","journal-title":"Nature"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.889372","article-title":"Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2","volume":"13","author":"Wines","year":"2022","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn4188","article-title":"Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities","volume":"8","author":"Chen","year":"2022","journal-title":"Sci Adv"},{"key":"B90","unstructured":"Influenza (Seasonal)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1038\/s41467-025-59149-8","article-title":"Antibody function predicts viral control in newborn monkeys immunised with an influenza virus HA stem nanoparticle","volume":"16","author":"Crofts","year":"2025","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-120617-041310","article-title":"Is a universal influenza virus vaccine possible","volume":"71","author":"Nachbagauer","year":"2020","journal-title":"Annu Rev Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2023.2223057","article-title":"Pathogenicity and virulence of influenza","volume":"14","author":"Liang","year":"2023","journal-title":"Virulence"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1172\/jci84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection","volume":"126","author":"DiLillo","year":"2016","journal-title":"J Clin Invest"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc\u03b3R interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.10.005","article-title":"Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase","volume":"56","author":"Lei","year":"2023","journal-title":"Immunity"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2016.05.014","article-title":"Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection","volume":"19","author":"Dunand","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00928-3","article-title":"Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice","volume":"8","author":"He","year":"2017","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1038\/s41467-024-47590-0","article-title":"Influenza antibody breadth and effector functions are immune correlates from acquisition of pandemic infection of children","volume":"15","author":"Jia","year":"2024","journal-title":"Nat Commun"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw262","article-title":"Generation and protective ability of influenza virus-specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection, and experimental challenge","volume":"214","author":"Jegaskanda","year":"2016","journal-title":"J Infect Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adu7646","article-title":"Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques","volume":"17","author":"Jacob-Dolan","year":"2025","journal-title":"Sci Transl Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41541-025-01340-5","article-title":"mRNA-1010 influenza vaccine elicits distinct and enhanced humoral immunity compared to adjuvanted inactivated vaccines","volume":"11","author":"Kaplonek","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821317116","article-title":"Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics","volume":"116","author":"Winarski","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00317","article-title":"Antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin head region of pandemic H1N1 influenza virus play detrimental roles in H1N1-infected mice","volume":"8","author":"Ye","year":"2017","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.04.003","article-title":"Influenza antigen engineering focuses immune responses to a subdominant but broadly protective viral epitope","volume":"25","author":"Bajic","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B106","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41572-023-00452-3","article-title":"HIV infection","volume":"9","author":"Bekker","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/nri2801","article-title":"Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design","volume":"10","author":"Zolla-Pazner","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2022.167924","article-title":"Understanding retroviral life cycle and its genomic RNA packaging","volume":"435","author":"Chameettachal","year":"2023","journal-title":"J Mol Biol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwab050","article-title":"Characteristics of the MACS\/WIHS Combined Cohort Study: Opportunities for research on aging with HIV in the longest US observational study of HIV","volume":"190","author":"D'Souza","year":"2021","journal-title":"Am J Epidemiol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101836","article-title":"Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: Evidence from routine care in Johannesburg, South Africa","volume":"57","author":"Brennan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.18632\/aging.101622","article-title":"Accelerated aging in perinatally HIV-infected children: Clinical manifestations and pathogenetic mechanisms","volume":"10","author":"Chiappini","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv218","article-title":"Precise quantitation of the latent HIV-1 reservoir: Implications for eradication strategies","volume":"212","author":"Crooks","year":"2015","journal-title":"J Infect Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10844","article-title":"Elimination of HIV-1-infected cells by broadly neutralizing antibodies","volume":"7","author":"Bruel","year":"2016","journal-title":"Nat Commun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.712122","article-title":"Broadly neutralizing antibodies for HIV-1 prevention","volume":"12","author":"Walsh","year":"2021","journal-title":"Front Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.027","article-title":"Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology","volume":"163","author":"Chung","year":"2015","journal-title":"Cell"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab3886","article-title":"Protective efficacy of adenovirus\/protein vaccines against SIV challenges in rhesus monkeys","volume":"349","author":"Barouch","year":"2015","journal-title":"Science"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02041-18","article-title":"Fc gamma receptor polymorphisms modulated the vaccine effect on HIV-1 risk in the HVTN 505 HIV vaccine trial","volume":"93","author":"Li","year":"2019","journal-title":"J Virol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41591-020-0774-y","article-title":"Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption","volume":"26","author":"Colby","year":"2020","journal-title":"Nat Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114344","article-title":"Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption","volume":"43","author":"Mdluli","year":"2024","journal-title":"Cell Rep"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.2174\/011570162X353682250314070148","article-title":"Fc functions and anti-HIV neutralizing antibodies: A perspective","author":"Vanderven","year":"2025","journal-title":"Curr HIV Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1086\/428405","article-title":"Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial","volume":"191","author":"Gilbert","year":"2005","journal-title":"J Infect Dis"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.106015","article-title":"Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions","volume":"231","author":"Schriek","year":"2024","journal-title":"Antiviral Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030009","article-title":"Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys","volume":"3","author":"Oswald","year":"2007","journal-title":"PloS Pathog"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against Ebola virus","volume":"19","author":"Saphire","year":"2018","journal-title":"Nat Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz364","article-title":"Survivors of Ebola virus disease develop polyfunctional antibody responses","volume":"221","author":"Gunn","year":"2020","journal-title":"J Infect Dis"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad555","article-title":"Long-term Sudan virus Ebola survivors maintain multiple antiviral defense mechanisms","volume":"230","author":"Sobarzo","year":"2024","journal-title":"J Infect Dis"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg6128","article-title":"Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects","volume":"13","author":"Meyer","year":"2021","journal-title":"Sci Transl Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.07.009","article-title":"A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus","volume":"24","author":"Gunn","year":"2018","journal-title":"Cell Host Microbe"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy285","article-title":"Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates","volume":"218","author":"Pascal","year":"2018","journal-title":"J Infect Dis"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00652-17","article-title":"Novel cross-reactive monoclonal antibodies against Ebolavirus glycoproteins show protection in a murine challenge model","volume":"91","author":"Duehr","year":"2017","journal-title":"J Virol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/srep45552","article-title":"Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-LEexposure treatment of Ebola virus infection","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"B139","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s42003-024-06556-0","article-title":"Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system","volume":"7","author":"Ilinykh","year":"2024","journal-title":"Commun Biol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.03.009","article-title":"A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus","volume":"54","author":"Gunn","year":"2021","journal-title":"Immunity"},{"key":"B141","unstructured":"Dengue - Global situation"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1205002","article-title":"Secretory pathways and multiple functions of nonstructural protein 1 in flavivirus infection","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-101416-041848","article-title":"The good, the bad, and the shocking: The multiple roles of dengue virus nonstructural protein 1 in protection and pathogenesis","volume":"5","author":"Glasner","year":"2018","journal-title":"Annu Rev Virol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004386","article-title":"Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera","volume":"10","author":"de Alwis","year":"2014","journal-title":"PloS Pathog"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02484-07","article-title":"Role of dendritic cells in antibody-dependent enhancement of dengue virus infection","volume":"82","author":"Boonnak","year":"2008","journal-title":"J Virol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0703498104","article-title":"Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention","volume":"104","author":"Goncalvez","year":"2007","journal-title":"PNAS"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1106568108","article-title":"Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection","volume":"108","author":"Chan","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107642","article-title":"Maternal anti-dengue IgG fucosylation predicts susceptibility to dengue disease in infants","volume":"31","author":"Thulin","year":"2020","journal-title":"Cell Rep"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266136","article-title":"Cross-reactive antibodies targeting surface-exposed non-structural protein 1 (NS1) of dengue virus-infected cells recognize epitopes on the spaghetti loop of the beta-ladder domain","volume":"17","author":"Kraivong","year":"2022","journal-title":"PloS One"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad122","article-title":"Soluble NS1 antagonizes IgG- and IgA- mediated monocytic phagocytosis of DENV infected cells","volume":"228","author":"Waldran","year":"2023","journal-title":"J Infect Dis"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1200195","article-title":"Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement","volume":"14","author":"Sarker","year":"2023","journal-title":"Front Immunol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jim.2016.11.005","article-title":"NK cell degranulation as a marker for measuring antibody-dependent cytotoxicity in neutralizing and non-neutralizing human sera from dengue patients","volume":"441","author":"Sun","year":"2017","journal-title":"J Immunol Methods"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7303","article-title":"Antibody fucosylation predicts disease severity in secondary dengue infection","volume":"372","author":"Bournazos","year":"2021","journal-title":"Science"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-023-01421-y","article-title":"Human FcgammaRIIIa activation on splenic macrophages drives dengue pathogenesis in mice","volume":"8","author":"Yamin","year":"2023","journal-title":"Nat Microbiol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2017.1254550","article-title":"The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis","volume":"15","author":"Gan","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1101\/2024.06.03.24308395","article-title":"Complement-dependent virion lysis mediated by dengue-Zika virus cross-reactive antibodies correlates with protection from severe dengue disease","author":"Dias","year":"2024","journal-title":"medRxiv"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.20329","article-title":"Dissecting antibody-dependent enhancement modulation by Fc-modified cross-neutralizing human monoclonal antibody","volume":"13","author":"Injampa","year":"2025","journal-title":"PeerJ"},{"key":"B158","doi-asserted-by":"publisher","first-page":"12987","DOI":"10.1038\/s41598-021-92403-9","article-title":"An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency","volume":"11","author":"Kotaki","year":"2021","journal-title":"Sci Rep"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095787","article-title":"Development of a cell-based assay measuring the activation of FcgammaRIIa for the characterization of therapeutic monoclonal antibodies","volume":"9","author":"Tada","year":"2014","journal-title":"PloS One"},{"key":"B160","article-title":"A cell-based reporter assay measuring the activation of fc gamma receptors induced by therapeutic monoclonal antibodies","volume-title":"Human monoclonal antibodies: methods and protocols","author":"Aoyama","year":"2018"},{"key":"B161","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jim.2014.07.010","article-title":"Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies","volume":"414","author":"Cheng","year":"2014","journal-title":"J Immunol Methods"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1548292","article-title":"ADCC: the rock band led by therapeutic antibodies, tumor and immune cells","volume":"16","author":"Vincken","year":"2025","journal-title":"Front Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"Ackerman","year":"2011","journal-title":"J Immunol Methods"},{"key":"B164","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nri3582","article-title":"The function of Fcgamma receptors in dendritic cells and macrophages","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1203954109","article-title":"Mouse model recapitulating human Fcgamma receptor structural and functional diversity","volume":"109","author":"Smith","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B167","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol Rev"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12861","article-title":"Prospects from systems serology research","volume":"153","author":"Arnold","year":"2018","journal-title":"Immunology"},{"key":"B170","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/mas.21771","article-title":"Methods for quantification of glycopeptides by liquid separation and mass spectrometry","volume":"42","author":"Yin","year":"2023","journal-title":"Mass Spectrom Rev"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-023-01359-1","article-title":"Fc-gammaR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2","volume":"8","author":"Mackin","year":"2023","journal-title":"Nat Microbiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1772257\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:31:27Z","timestamp":1778477487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1772257\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":171,"alternative-id":["10.3389\/fimmu.2026.1772257"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1772257","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1772257"}}